Abstract
While most inhibitors of histone deacetylases (HDACs) are hydroxamic acid derivatives, several nonhydroxamates have recently been developed as inhibitors and attracted quite a deal of attention. In this review, we present the rational design, inhibitory effect and antiproliferative activity of non-hydroxamate HDAC inhibitors.
Keywords: Histone deacetylase, inhibitor, hydroxamic acid, non-hydroxamate, zinc enzyme, rational drug design, anticancer agent
Mini-Reviews in Medicinal Chemistry
Title: Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors
Volume: 6 Issue: 5
Author(s): Takayoshi Suzuki and Naoki Miyata
Affiliation:
Keywords: Histone deacetylase, inhibitor, hydroxamic acid, non-hydroxamate, zinc enzyme, rational drug design, anticancer agent
Abstract: While most inhibitors of histone deacetylases (HDACs) are hydroxamic acid derivatives, several nonhydroxamates have recently been developed as inhibitors and attracted quite a deal of attention. In this review, we present the rational design, inhibitory effect and antiproliferative activity of non-hydroxamate HDAC inhibitors.
Export Options
About this article
Cite this article as:
Suzuki Takayoshi and Miyata Naoki, Rational Design of Non-Hydroxamate Histone Deacetylase Inhibitors, Mini-Reviews in Medicinal Chemistry 2006; 6 (5) . https://dx.doi.org/10.2174/138955706776876186
DOI https://dx.doi.org/10.2174/138955706776876186 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ascorbic Acid in Cancer Chemoprevention: Translational Perspectives and Efficacy
Current Drug Targets Prevention of Colitis-associated Cancer: Natural Compounds that Target the IL-6 Soluble Receptor
Anti-Cancer Agents in Medicinal Chemistry Structural Biology of Bacterial Secretion Systems in Gram-Negative Pathogens- Potential for New Drug Targets
Infectious Disorders - Drug Targets Effects of Oxymatrine from Ku Shen on Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Oxidative and Nitrosative Stress and Immune-inflammatory Pathways in Patients with Myalgic Encephalomyelitis (ME)/Chronic Fatigue Syndrome (CFS)
Current Neuropharmacology Circadian Cycle and Chronotherapeutics: Recent Trend for the Treatment of Various Biological Disorders
Recent Patents on Drug Delivery & Formulation Beneficiary and Adverse Effects of Phytoestrogens: A Potential Constituent of Plant-based Diet
Current Pharmaceutical Design Nutrition and Bone Health: Its Relationship to Osteoporosis
Current Nutrition & Food Science Oncogenomics
Current Drug Metabolism Implications of Fibroblast Growth Factors (FGFs) in Cancer: From Prognostic to Therapeutic Applications
Current Drug Targets Boronated Compounds for Imaging Guided BNCT Applications
Anti-Cancer Agents in Medicinal Chemistry Hepatoma-Derived Growth Factor in Carcinogenesis and Cancer Progression
Current Drug Therapy Natural Monoclonal Antibodies and Cancer
Recent Patents on Anti-Cancer Drug Discovery Lipases in Medicine: An Overview
Mini-Reviews in Medicinal Chemistry Recent Progress in the Field of β-(1,3)-Glucans and New Applications
Mini-Reviews in Medicinal Chemistry Recent Advances in Receptor-Targeted Fluorescent Probes for In Vivo Cancer Imaging
Current Medicinal Chemistry Platinum Compounds: A Hope for Future Cancer Chemotherapy
Anti-Cancer Agents in Medicinal Chemistry Nanowired Drug Delivery of Antioxidant Compound H-290/51 Enhances Neuroprotection in Hyperthermia-Induced Neurotoxicity
CNS & Neurological Disorders - Drug Targets Cardioprotective effects of Aronia melanocarpa anthocynanins. From laboratory experiments to clinical practice.
Current Pharmaceutical Design microRNA, Cancer and Cancer Chemoprevention
Current Molecular Pharmacology